张庆雪 张莹莹 高东程 赵硕 李靖若

郑州大学第一附属医院乳腺外科,郑州 450052

通信作者:李靖若,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

DOI:10.3760/cma.j.issn.1671-0290.2023.02.023

任荣鑫 赵红艺

北京医院整形外科 国家老年医学中心 中国医学科学院老年医 学 研 究 院,北 京

100730

通信作者:赵红艺,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

DOI:10.3760/cma.j.issn.1671-0290.2023.03.020

Treatment with high-intensity statins, such as atorvastatin 20 mg upwards, results in a 36% proportional increase in new type 2 diabetes diagnoses compared to placebo, with the majority of the new diabetes occurring in people already close to the diabetes glycaemic threshold, according to this meta-analysis of participant-level data from the Cholesterol Treatment Trialists’ Collaboration published in The Lancet Diabetes & Endocrinology. A smaller 10% proportional increase occurs with low- or moderate-intensity statins. Although previous meta-analyses of summary data from the statin trials have highlighted this increased risk, they could not fully quantify the size and timing of increases or determine who is at greatest risk. People with pre-existing diabetes treated with statins are also at risk of worsening glycaemia, particularly with high-intensity statins. However, the benefits of statins in reducing cardiovascular events in those at high risk far outweigh the impact of these increases in incident type 2 diabetes, so this study should not change prescribing habits. Nonetheless, it reminds us of the importance of counselling regarding increasing glycaemia risk and of encouraging lifestyle discussions around weight, eating patterns, sleep and physical activity, which can not only reduce the risk of type 2 diabetes but also improve the cardiovascular risk the statin is being used to treat.

Pam Brown

GP in Swansea

Citation: Brown P (2024) Diabetes Distilled: Statin heart benefits outweigh diabetes risks. Diabetes & Primary Care 26: [Early view publication]

Effective management of exudate is crucial for ensuring timely wound healing. Summarised in this product focus are 11 clinical studies (incorporating the experience of 179 patients), indicating that the ActivHeal® PHMB Foam dressing range (Advanced Medical Solutions Ltd.) is effective at treating infected wounds, managing wound exudate, debridement/wound cleansing, and enhancing the quality of life in patients with a various wound types, including venous leg ulcers (VLU), diabetic foot ulcers (DFU), pressure ulcers (PU), burns and postoperative surgical wounds. The use of the antimicrobial agent polyhexamethylene biguanide (PHMB) provides an effective defence against a broad spectrum of microorganisms, including antibiotic-resistant microorganisms, commonly associated with wound colonisation and infection. This evaluation does not aim to be a systematic or narrative review but rather a selection of the most pertinent publications summarising the clinical evidence supporting ActivHeal PHMB Foam range for the treatment of various chronic and acute wounds.

Rebecca Forder

Senior Clinical Research Manager, Advanced Medical Solutions, Winsford, UK

Alan A Rogers

Independent Wound Care Consultant, Flintshire, UK

Karen Ousey

Professor of Skin Integrity, Director for the Institute of Skin Integrity and Infection Prevention, Department of Nursing and Midwifery, University of Huddersfield, Huddersfield, UK

Mark G Rippon

Visiting Clinical Research Fellow, Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Queensgate, Huddersfield, UK

Key words

• ActivHeal PHMB Foam
• Exudate management
• Infected wounds
• Wound healing

Declaration of interest

This publication was supported by Advanced Medical solutions.